These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38553708)

  • 1. Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD).
    Zeng A; Yin Y; Xu Z; Abuduwayiti A; Yang F; Shaik MS; Wang C; Chen K; Wang C; Fang X; Dai J
    BMC Cancer; 2024 Mar; 24(1):396. PubMed ID: 38553708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAIT cells are associated with responsiveness to neoadjuvant immunotherapy in COPD-associated NSCLC.
    Yin Y; Zeng A; Abuduwayiti A; Xu Z; Chen K; Wang C; Fang X; Wang J; Jiang G; Dai J
    Cancer Med; 2024 Mar; 13(6):e7112. PubMed ID: 38509769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of chronic obstructive pulmonary disease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study.
    Dong W; Yin Y; Yang S; Liu B; Chen X; Wang L; Su Y; Jiang Y; Shi D; Sun D; Qin J
    BMC Cancer; 2024 Jan; 24(1):153. PubMed ID: 38291354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the spatial immune landscape of CD103
    Yang G; Hu M; Cai S; Li C; Yang L; Zhao M; Jing H; Xing L; Sun X
    Cell Oncol (Dordr); 2024 Oct; 47(5):1957-1971. PubMed ID: 39158668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
    Cheng H; Janakiram M; Borczuk A; Lin J; Qiu W; Liu H; Chinai JM; Halmos B; Perez-Soler R; Zang X
    Clin Cancer Res; 2017 Feb; 23(3):825-832. PubMed ID: 27553831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of severe-to-very severe chronic obstructive pulmonary disease on the prognosis of patients with non-small cell lung cancer who received chemotherapy.
    Dong W; Zhu Y; Du Y; Wang L; Feng X; Ma S
    Clin Respir J; 2020 Apr; 14(4):345-352. PubMed ID: 31876095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study.
    Zhai W; Zhang C; Duan F; Xie J; Dai S; Lin Y; Yan Q; Rao B; Li L; Zhou Y; Zhao Z; Long H; Wang J
    Front Immunol; 2024; 15():1422717. PubMed ID: 39108262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of CD4(+) and CD8(+) T cells in tumor islets and stroma from patients with non-small cell lung cancer in association with COPD and smoking.
    Jackutė J; Žemaitis M; Pranys D; Šitkauskienė B; Miliauskas S; Bajoriūnas V; Sakalauskas R
    Medicina (Kaunas); 2015 Nov; 51(5):263-71. PubMed ID: 26674143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing.
    Hu J; Zhang L; Xia H; Yan Y; Zhu X; Sun F; Sun L; Li S; Li D; Wang J; Han Y; Zhang J; Bian D; Yu H; Chen Y; Fan P; Ma Q; Jiang G; Wang C; Zhang P
    Genome Med; 2023 Mar; 15(1):14. PubMed ID: 36869384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of neoadjuvant immunotherapy on pulmonary function and perioperative outcomes in patients with resectable non-small cell lung cancer].
    Zhu Y; Li JQ; Chang Q; Qiang HP; Lu JH; Feng H; Shen YC; Qian JL; Chu TQ
    Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):393-398. PubMed ID: 35144337
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer.
    Shen J; Gu L; Qi Y; Yao Y; Lu S; Chen Z
    Front Immunol; 2023; 14():1268251. PubMed ID: 37818382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open, observational, three-arm clinical study of 2-3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis.
    Gu L; Wang X; Sun Y; Xu Y; Niu X; Zhao R; Yao Y; Jian H; Han Y; Wei J; Chen Z; Lu S
    Front Immunol; 2022; 13():938269. PubMed ID: 36059450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study.
    Li C; Wu J; Jiang L; Zhang L; Huang J; Tian Y; Zhao Y; Liu X; Xia L; E H; Gao P; Hou L; Yang M; Ma M; Su C; Zhang H; Chen H; She Y; Xie D; Luo Q; Chen C
    Cancer Immunol Immunother; 2023 Mar; 72(3):783-794. PubMed ID: 36056951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
    Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of circulating tumor cells in monitoring the efficacy of neoadjuvant immunotherapy for non-small cell lung cancer].
    Li YJ; Chen H; Liao JF; Yuan JL; Chen T; Zhu J
    Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Feb; 55(2):233-238. PubMed ID: 34645185
    [No Abstract]   [Full Text] [Related]  

  • 16. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
    Sawa K; Koh Y; Kawaguchi T; Kambayashi S; Asai K; Mitsuoka S; Kimura T; Yoshimura N; Yoshimoto N; Kubo A; Saka H; Matsumura A; Wanibuchi H; Yamamoto N; Nishiyama N; Hirata K
    Lung Cancer; 2017 Oct; 112():96-101. PubMed ID: 29191607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Analysis of Immune Responses to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.
    Liu W; Chen C; Li C; Wu X; Ma Y; Xie J; Wang D; Xu F; Zheng X; Zhang Z; Wang C; Yue D; Zhang B
    Ann Surg Oncol; 2024 Dec; 31(13):9332-9343. PubMed ID: 39190094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
    Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease.
    Shin SH; Park HY; Im Y; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee HY; Lee SH
    Int J Cancer; 2019 Nov; 145(9):2433-2439. PubMed ID: 30807641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.